Navigation Links
Low Dose Anti Rejection Protocol Helps Intestinal Transplant Recipients

Rakesh Sindhi, a surgeon and a researcher at the children hospital of Pittsburgh is planning to present how the new low dose anti rejection protocol //has appreciably improved the outcomes of the intestinal transplant recipients.

Research performed by Rakesh Sindhi, MD, Co-Director of Pediatric Transplantation, and associates at Children's Hospital of Pittsburgh, shows that the new protocol reduces drug doses and eliminates steroids altogether in young patients. Dr. Sindhi, also an Associate Professor of Surgery at the University of Pittsburgh School of Medicine, will present four studies at the World Transplant Congress in Boston on July 24 and 25, 2006 – with all ranking in the top 10 percent of all research selected.A total of 75 Children's patients, who have received an intestine transplant, alone or with the liver over a four-year period using the new protocol, were reviewed.

The results show a survival rate of 84 percent in the third year of follow-up. Comparably, the international survival rate average for intestine transplant recipients is 70 percent in the second year follow-up. The anti-rejection protocol was originally proposed by Thomas E Starzl, MD, PhD, in 2000 at the University of Pittsburgh. ‘We were pleased and encouraged by the results of this protocol, which included greatly reduced infections, lymphoma-like disorders, and measurable benefits in the rate of height and weight gain, than were seen with previous higher dose regimens,’ Dr. Sindhi said. Improved survival rates have focused more attention on finding ways to make recovery less difficult and give children a quality of life vastly better than what patients could expect a decade earlier. The most difficult period of recovery for child and family is typically the first year after transplantation.

As the child's condition improves, improvement in the child's quality of life typically follows. Also being presented are two new strategies being developed in Children
'"/>




Page: 1 2

Related medicine news :

1. A Urine Test Could Predict Rejection In Transplant Patients
2. Rejection Rate for Liver Transplants Patient Reduced
3. Peer Rejection Leads To Reduced Participation In Classroom Activities
4. Inhaled Cyclosporine Results In Rejection Free Survival among Lung Transplant Patients
5. Survey Reveals Rejection of NHS Database Scheme
6. Ontario Supports OHIP’s Rejection of Claim by North York Ma
7. Stem Cell Finding Could Help Reduce Transplant Rejection
8. New Screening Protocol Identifies More Case Of Lynch Syndrome
9. New Protocol Targets Aggressive Brain Cancer
10. Antibiotics Helps Autism
11. Serum Progesterone Helps Stratify Ectopic Pregnancy Risk
Post Your Comments:
(Date:12/6/2009)... advised to avoid oysters harvested from San Antonio Bay ... The U.S. Food and Drug Administration is advising consumers ... Bay on or after Nov. 16 due to reports ... oysters harvested from this area, which is located on ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ,, The FDA, along with the ...
(Date:12/6/2009)... that the loss of a key segment of DNA can ... to show that this kind of genetic alteration can cause ... , The study, led by Dr Sadaf Farooqi from the ... Trust Sanger Institute, looked at 300 children with severe obesity. ... types of mutation known as copy number variants (CNVs). CNVs ...
(Date:12/6/2009)... feline DNA in virus , , SUNDAY, Dec. 6 (HealthDay News) ... be found in a tiger that lived thousands or millions ... the virus took on a bit of a tiger,s genetic ... in the virus to this day. That tiger, in fact, ... the virus that ultimately led to its infection of humans. ...
(Date:12/6/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... pivotal Phase 2b 003-A1 study, known as the ... heavily pre-treated relapsed and refractory multiple myeloma patients. ... Joint Symposium at the 51st annual meeting of ... Orleans. Enrollment in this trial is complete (n=269), ...
(Date:12/6/2009)... Dec. 6 Blood clotting, or coagulation, ... when a blood vessel is injured. Sometimes, however, ... an obvious injury or do not dissolve naturally, ... today at the 51st Annual Meeting of the ... of using the anticoagulants aspirin and heparin with ...
Breaking Medicine News(10 mins):Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:AIDS May Date Back to Ancient Tiger 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7
... who do drop risk of premature birth, smaller babies ... who quit smoking before the 15th week of pregnancy ... babies to that of nonsmoking women, a new study ... the risk of miscarriage, ectopic pregnancy, premature birth, small ...
... Hancock Medical Center for Making Quality of Care "No. 1 Priority" ... ... in Bay Saint Louis, Miss., was named Mississippi Hospital of the ... Awards on March 2. The hospital, a QHR management client ...
... Pregis Corporation, a leading international manufacturer, marketer, and ... today announced its 2008 fourth quarter and full year ... generated net sales of $219.6 million, a decrease of ... fourth quarter of 2007. Excluding incremental revenue from ...
... Study finds it suppresses enzyme vital to tumor growth , , ... combat AIDS may also help slow the spread of a ... , A study published in the current issue of the ... suppresses the enzyme telomerase. Telomerase activity appears to be essential ...
... Health and Safety and Pharmaceutical Innovation First ... Pharmaceutical Association (GPhA) released the following statement ... Jaeger regarding the bipartisan Senate introduction of ... Medicine Act.""Momentum is skyrocketing for biogenerics legislation ...
... common drugs, study finds , , THURSDAY, March 26 (HealthDay ... can be triggered by some commonly used heart medications, ... the condition followed injections of adrenaline or dobutamine, according ... issue of the Journal of the American College ...
Other Medicine News:Health News:Newly Pregnant Smokers Have a 15-Week Window to Quit 2Health News:QHR Management Client Hancock Medical Center Named Mississippi Hospital of the Year 2Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 2Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 3Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 4Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 5Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 6Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 7Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 8Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 9Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 10Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 11Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 12Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 13Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 14Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 15Health News:GPhA Statement on the Introduction of the Bipartisan Senate Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act' 2Health News:What Causes Mystery Heart Condition? 2Health News:What Causes Mystery Heart Condition? 3
(Date:12/7/2009)... /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd.,announced today ... data for TG-0054,the Company,s chemokine receptor CXCR4 ... at the ASH Annual Meeting held in ... 8, 2009. , ... will be presented. In this randomized,double-blind, placebo-controlled, ...
(Date:12/7/2009)... RAPIDS, Mich., Dec. 7 On December ... on its eight-story, $178 million, 240,000 square foot ... and scientific opportunity both for VAI and West ... the more than $1 billion investment in infrastructure ... When operating at capacity, the expansion will support ...
(Date:12/7/2009)... ,, 60 people, males and females, ... antibodies generated by the vaccine specifically identified several ... BiondVax,s CEO Dr. Ron Babecoff: "This is ... realization of the Company,s vision of ensuring protection ... , BiondVax Pharmaceuticals Ltd. (TASE: ...
Breaking Medicine Technology:TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2Van Andel Institute Cuts Ribbon on $178 Million Expansion 2Van Andel Institute Cuts Ribbon on $178 Million Expansion 3Van Andel Institute Cuts Ribbon on $178 Million Expansion 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5XELR8 Holdings Inc Hires Vice President of Strategy and Network Development 48585 1XELR8 Holdings Inc Hires Vice President of Strategy and Network Development 48585 2XELR8 Holdings Inc Hires Vice President of Strategy and Network Development 48585 3New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 1New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 2New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 3New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 4New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 5New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 6First and Only Weaning Product Based on 100 25 Non Allergenic Amino Acids Specifically Designed for Children With Cows Milk Protein Allergy and Multip 48577 1First and Only Weaning Product Based on 100 25 Non Allergenic Amino Acids Specifically Designed for Children With Cows Milk Protein Allergy and Multip 48577 2First and Only Weaning Product Based on 100 25 Non Allergenic Amino Acids Specifically Designed for Children With Cows Milk Protein Allergy and Multip 48577 3
... and data management system ,RADIANCE is ... needs of data management systems (DMS), and ... of STAT analyzer systems., ,The RADIANCE software ... for both STAT analyzers and hospital and ...
... syngo Dynamics network is ... and archiving system using evidence-based ... of clinical procedures. It has ... practical reality for hospital echocardiography ...
... AXIOM Artis dTC is a versatile ... the cardiology department from preparation to ... interventional procedures. With AXIOM Artis dTC, your ... the cardiology department that leaves you free ...
... ACUSON Cypress cardiovascular system ... worlds first portable, high-performance transesophageal ... highly miniaturized, all-digital, phased array ... studies and outstanding images, even ...
Medicine Products: